Benitec Biopharma Q1 net loss $6M; 19 OPMD subjects enrolled; BB-301 dosing expected Dec/Jan

Benitec Biopharma Inc.

2024-Q1 EPS reported -$2.76

Net loss of $6.0M ($2.76 per share) vs $5.1M ($7.98 per share) in Q1 FY2023; higher share count reduced per-share loss.
Cash and equivalents $25.9M at Sep 30, 2023, up from $2.5M at Jun 30, 2023, extending runway.
R&D expense $4.4M (up 66% YoY) driven by BB-301 clinical development; G&A $1.6M (down 19% YoY).
19 subjects enrolled in OPMD Natural History Study as of Oct 2023; first BB-301 dose planned Dec 2023 or Jan 2024.
FDA IND clearance received; Canadian REB submission completed; interim safety/efficacy data expected within 12 months of first dose.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Benitec Biopharma Inc. reported First Fiscal Quarter ended September 30, 2023 results: revenue $0.

Period: First Fiscal Quarter ended September 30, 2023
Revenue: $0
Result: reported results

Exact text from the filing

OPMD patient screening and enrollment to begin in Canada. Financial Highlights First Quarter 2024 Financial Results Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022. Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Benitec Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-275384

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.